Amenamevir

Clinical data
Trade names	Amenalief
Other names	ASP-2151, ASP2151
ATC code	J05AX26 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide;
CAS Number	841301-32-4;
PubChem CID	11397521;
DrugBank	11701;
ChemSpider	9572421;
UNII	94X46KW4AE;
KEGG	D10564;
CompTox Dashboard (EPA)	DTXSID101027753 ;
Chemical and physical data
Formula	C24H26N4O5S
Molar mass	482.56 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1;
	InChI InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29); Key:MNHNIVNAFBSLLX-UHFFFAOYSA-N;

Amenamevir

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

It acts as an inhibitor of the zoster virus's helicase–primase complex.[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]

References

^ Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. (November 2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.
^ Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917. S2CID 43813287.
^ "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017. Archived from the original on March 1, 2021. Retrieved August 3, 2018.

This antiinfective drug article is a stub. You can help Wikipedia by adding missing information.

[1] Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. (November 2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.

[2] Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917. S2CID 43813287.

[3] "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017. Archived from the original on March 1, 2021. Retrieved August 3, 2018.

See also

References